- Home
- DDI vs MNPR Comparison
DDI vs MNPR Comparison
Compare DDI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDI | MNPR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.3M | 421.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DDI | MNPR |
|---|---|---|
| Price | $8.94 | $70.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $19.25 | ★ $101.42 |
| AVG Volume (30 Days) | 72.5K | ★ 343.0K |
| Earning Date | 02-10-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.12 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $346,122,000.00 | N/A |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | $7.89 | N/A |
| P/E Ratio | $3.86 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $8.09 | $26.06 |
| 52 Week High | $11.25 | $105.00 |
Technical Indicators
Market Signals| Indicator | DDI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 54.51 |
| Support Level | $8.59 | $67.33 |
| Resistance Level | $9.10 | $72.75 |
| Average True Range (ATR) | 0.26 | 5.71 |
| MACD | 0.01 | 1.29 |
| Stochastic Oscillator | 54.92 | 92.77 |
Price Performance
Historical ComparisonAbout DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.